featured
ASCO 2015 Recap: Renal Cell Carcinoma
Interview by
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Motzer R, Hutson T, Glen H, et al Randomized phase II, three-arm trial of lenvatinib [LEN], everolimus [EVE], and LEN+EVE in patients with metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4506.
- Bjarnason GA, Knox JJ, Kollmannsberger CK, et al. Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4555.
- Armstrong AJ, Broderick S, Eisen T, et al. Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma [ASPEN]. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4507.
- Hammers HJ, Plimack ER, Infante JR, et al. Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4516.
- Plimack ER, Hammers HJ, Rini BI, et al. Updated survival results from a randomized, dose-ranging phase II study of nivolumab in metastatic renal cell carcinoma. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 4553.
- Liu X, Hoang A, Zhou L, et al. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma [published online May 26, 2015]. Cancer Immunol Res. doi: 10.1158/2326-6066.CIR-14-0244.
Disclosure statements are available on the authors' profiles: